Company: BDRX
Filing Date: 2025-06-02
Form Type: 424B3
Source: 0001214659-25-008714
Chunk: 1

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-06-02
Form: 424B3
Chunk 1
---
 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2025

Commission File Number: 001-37652

Biodexa Pharmaceuticals PLC
(Translation of registrant's name into English)

1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom
(Address of principal executive office)</div>

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨

The information in the attached Exhibit 99.1 is being furnished and shall not be
deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company
under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth
by specific reference in such a filing.

<div align='center'>SUBMITTED HEREWITH:</div>

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: May 30, 2025 |     | Biodexa Pharmaceuticals PLC                      
 (Registrant)                                     
 /s/ Stephen Stamp                                |
|:-------------------|:----|:-------------------------------------------------|
|                    |     | Stephen Stamp                                    |
|                    |     | Chief Executive Officer, Chief Financial Officer |

EXHIBIT 99.1

<div align='center'>Shareholder Update</div>

May 30, 2025

<div align='center'>Biodexa Pharmaceuticals PLC

Shareholder Update</div>

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)
(Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases
with unmet medical needs, today announced a brief update for shareholders.

Financial position
As of May 29, 2025, the Company had access to the following cash resources:

|                                               |     | $ millions |
| Cash at bank                                  |     |